批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/02/15 |
SUPPL-43(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/10/04 |
SUPPL-39(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/10/04 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/09/01 |
SUPPL-40(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/11/01 |
SUPPL-35(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/09/01 |
SUPPL-33(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2014/07/31 |
SUPPL-32(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/05/20 |
SUPPL-30(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2013/05/20 |
SUPPL-29(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2013/05/20 |
SUPPL-28(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2013/04/24 |
SUPPL-31(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2004/08/06 |
SUPPL-24(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/01/28 |
SUPPL-19(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/05/03 |
SUPPL-15(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2002/05/03 |
SUPPL-14(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2002/05/03 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/03/28 |
SUPPL-17(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2002/02/22 |
SUPPL-16(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/07/09 |
SUPPL-13(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2000/09/29 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1999/10/29 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1999/07/30 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1999/03/26 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/01/08 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1997/09/26 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1997/09/25 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1997/09/23 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1997/09/15 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1997/09/15 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1996/07/31 |
ORIG-1(原始申请) |
Approval |
Type 5 - New Formulation or New Manufacturer |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:ESTRADIOL 剂型/给药途径:SYSTEM;TRANSDERMAL 规格:0.0375MG/24HR 治疗等效代码:AB1
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020538 |
005 |
NDA |
VIVELLE-DOT |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.0375MG/24HR |
Prescription |
Yes |
No |
AB1 |
1999/01/08
|
SANDOZ |
201675 |
002 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.0375MG/24HR |
Prescription |
No |
No |
AB1 |
2014/12/19
|
MYLAN TECHNOLOGIES |
211293 |
002 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.0375MG/24HR |
Prescription |
No |
No |
AB1 |
2019/02/04
|
AMNEAL |
206241 |
002 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.0375MG/24HR |
Prescription |
No |
No |
AB1 |
2022/12/01
|
ZYDUS PHARMS |
活性成分:ESTRADIOL 剂型/给药途径:SYSTEM;TRANSDERMAL 规格:0.05MG/24HR 治疗等效代码:AB1
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020538 |
006 |
NDA |
VIVELLE-DOT |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.05MG/24HR |
Prescription |
Yes |
No |
AB1 |
1999/01/08
|
SANDOZ |
201675 |
003 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.05MG/24HR |
Prescription |
No |
No |
AB1 |
2014/12/19
|
MYLAN TECHNOLOGIES |
211293 |
003 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.05MG/24HR |
Prescription |
No |
No |
AB1 |
2019/02/04
|
AMNEAL |
206241 |
003 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.05MG/24HR |
Prescription |
No |
No |
AB1 |
2022/12/01
|
ZYDUS PHARMS |
活性成分:ESTRADIOL 剂型/给药途径:SYSTEM;TRANSDERMAL 规格:0.075MG/24HR 治疗等效代码:AB1
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020538 |
007 |
NDA |
VIVELLE-DOT |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.075MG/24HR |
Prescription |
Yes |
No |
AB1 |
1999/01/08
|
SANDOZ |
201675 |
004 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.075MG/24HR |
Prescription |
No |
No |
AB1 |
2014/12/19
|
MYLAN TECHNOLOGIES |
211293 |
004 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.075MG/24HR |
Prescription |
No |
No |
AB1 |
2019/02/04
|
AMNEAL |
206241 |
004 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.075MG/24HR |
Prescription |
No |
No |
AB1 |
2022/12/01
|
ZYDUS PHARMS |
活性成分:ESTRADIOL 剂型/给药途径:SYSTEM;TRANSDERMAL 规格:0.1MG/24HR 治疗等效代码:AB1
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020538 |
008 |
NDA |
VIVELLE-DOT |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.1MG/24HR |
Prescription |
Yes |
Yes |
AB1 |
1999/01/08
|
SANDOZ |
201675 |
005 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.1MG/24HR |
Prescription |
No |
No |
AB1 |
2014/12/19
|
MYLAN TECHNOLOGIES |
211293 |
005 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.1MG/24HR |
Prescription |
No |
No |
AB1 |
2019/02/04
|
AMNEAL |
206241 |
005 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.1MG/24HR |
Prescription |
No |
No |
AB1 |
2022/12/01
|
ZYDUS PHARMS |
活性成分:ESTRADIOL 剂型/给药途径:SYSTEM;TRANSDERMAL 规格:0.025MG/24HR 治疗等效代码:AB1
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020538 |
009 |
NDA |
VIVELLE-DOT |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.025MG/24HR |
Prescription |
Yes |
No |
AB1 |
2002/05/03
|
SANDOZ |
201675 |
001 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.025MG/24HR |
Prescription |
No |
No |
AB1 |
2014/12/19
|
MYLAN TECHNOLOGIES |
211293 |
001 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.025MG/24HR |
Prescription |
No |
No |
AB1 |
2019/02/04
|
AMNEAL |
206241 |
001 |
ANDA |
ESTRADIOL |
ESTRADIOL |
SYSTEM;TRANSDERMAL |
0.025MG/24HR |
Prescription |
No |
No |
AB1 |
2022/12/01
|
ZYDUS PHARMS |